



Sheet 1 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DCKET NO.  
2026-4230US1SERIAL NO.  
09/155,590**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

APPLICANT(S)  
Jeffrey Schlom et alFILING DATE  
September 30, 1998GROUP ART UNIT  
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
HAZ	2,253,211	2/9/92	GB				
HAZ	WO 89/06974	8/10/89	WO				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

HAZ	HAZ	Rotzschke, O. et al, Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells, <u>Nature</u> 1990, 348:252-254.
HAZ	HAZ	Skipper, J. et al, Identification of Two Cytotoxic T Lymphocyte-recognized Epitopes in the Ras Protein, <u>The Journal of Experimental Medicine</u> , 177 (5), 1993, 1493-1498.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2026-4230US1SERIAL NO.  
09/155,590**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*APPLICANT(S)  
Jeffrey Schiom et alFILING DATE  
September 30, 1998GROUP ART DMT  
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

		Abrams, S.I. et al, Mutant <i>ras</i> epitopes as targets for cancer vaccines, <u>Sem. Oncol.</u> 23, 118-134 (1996).
		Eishenlohr, L.C. et al, A transient transfection system for identifying biocynthesized proteins processed and presented to class I MHC restricted T lymphocytes, <u>J. Immunol. Meth.</u> , 1992, 154:131.

EXAMINER

DATE CONSIDERED

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

All references considered except where lined through. /KAC/

/Karen A. Canella/ 7/15/2009



Sheet 3 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2026-4230US1SERIAL NO.  
09/155,590**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*APPLICANT(S)  
Jeffrey Schlom et alFILING DATE  
September 30, 1998GROUP ART UNIT  
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Papers, etc.)**

AKC		Peace, D.J. et al, T cell recognition of transforming proteins encoded by mutated <i>ras</i> proto-oncogenes, <i>J. Immunol.</i> , 146, 2059-2065, (1991).
AKC		Takahashi, H.S. et al, A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp 160, <i>Science</i> , 1989, Vol. 246, 118-121.

EXAMINER

Hope Robinson Eubank

DATE CONSIDERED

3/22/99 10/5/00

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

All references considered except where lined through. /KAC/

/Karen A. Canella/ 7/15/2009



Sheet 4 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DCKET NO.  
2026-4230US1SERIAL NO.  
09/155,590

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)  
Jeffrey Schlom et alFILING DATE  
September 30, 1998GROUP ART UNIT  
1643

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Rock, K.L. et al, Analysis of the association of peptides of optimal length to class I molecules or the surface of cells, Proc. Natl. Acad. Sci. USA 1992, Vol. 89, 8918-8922.
	Mitsudomi, T. et al, P53 mutation in non small lung cancer cell line and their correlation with the presence of ras mutations and clinical features, Oncogene 1992, Vol. 7, No. 1, 171-180.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/



Sheet 5 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2026-4230US1SERIAL NO.  
09/155,590**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*APPLICANT(S)  
Jeffrey Schlom et alFILING DATE  
September 30, 1998GROUP ART UNIT  
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

	Kahn, S.M. et al, Rapid and sensitive nonradioactive detection of mutant K-ras genes via enriched PCR amplification, <u>Oncogene</u> , Vol. 6, No. 6, 1079-1083 (1991).
	Fenton, R.G. et al, Cytotoxic T-Cell Response and In Vivo Protection Against Tumor Cells Harboring Activated ras Proto-oncogenes, <u>Journal of the National Cancer Institute</u> , Vol. 85, No. 16, August 18, 1993.

EXAMINER

DATE CONSIDERED

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2026-42300S1SERIAL NO.  
09/155,590**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*APPLICANT(S)  
Jeffrey Schlom et alFILING DATE  
September 30, 1998GROUP ART UNIT  
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

		Tsang, K.Y. et al, Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine, <u>J. Natl. Cancer Inst.</u> , Vol. 87, No. 13, July 1995, 982-990.
		Hamer, P.J. et al, Activated Val-12 <i>ras</i> p21 in cell culture fluids and mouse plasma, <u>Oncogene</u> , Vol. 6, No. 9, 1609-1615 (1991).

EXAMINER

DATE CONSIDERED

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/



Sheet 1 of 11

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2026-4230US1SERIAL NO.  
09/155,590**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

APPLICANT(S)  
Jeffrey Schlom et alFILING DATE  
September 30, 1998GROUP ART UNIT  
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

HAC		Carter, G. et al, <u>Ras mutations in patients following cytotoxic therapy for lymphoma, Oncogene,</u>
		Vol. 5, No. 3, 1990, 411-416.
HAC		Fenton, R.G. et al, Induction of T-Cell Immunity Against <u>Ras Oncoproteins by Soluble Protein</u>
		or <u>Ras-Expressing Escherichia coli</u> , <u>Journal of the National Cancer Institute (Bethesda)</u> , Vol. 87, No. 24, 1995, 1853-1861.

EXAMINER

DATE CONSIDERED

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2026-4230US1SERIAL NO.  
09/155,5904**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*APPLICANT(S)  
Jeffrey Schlom et alFILING DATE  
September 30, 1996GROUP ART UNIT  
1843**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

		Capon, D. J. et al, Activation of Ki-ras 2 gene in human colon and lung carcinomas by two different point mutations, <u>Nature</u> , Vol. 304, No. 11, August 1983, 507-513.
		Bos, J.L., The <i>ras</i> gene family and human carcinogenesis, <u>Mutation Research</u> , 195 (1988), 255-271.

**EXAMINER****DATE CONSIDERED****EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC/

/Karen A. Caneilla/ 7/15/2009/



**SERIAL NO.**  
**09/155.5904**

FORM PTO-1449

### INFORMATION DISCLOSURE CITATION

*(Use several sheets if necessary)*

**APPLICANT(S)**  
**Jeffrey Schlom et al**

**FLING DATE**  
**September 30, 1996**

GROUP ABT OMIT  
1643

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

HAR		Van Bleek, G. et al, Isolation of an endogenously processed immunodominant viral peptide from
		the class I H-2K molecule, <u>Nature</u> 1990, 348:213-216.
HAR		Mitsudomi, T. et al, <i>Ras</i> gene mutation in non small lung cancer are associated with shortened
		survival irrespective of treatment intent, <u>Cancer Research</u> 1991, 51:4999-5002.

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/



Sheet 10 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DCKET# NO.  
2026-4230US1SERIAL NO.  
09/155,590**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*APPLICANT(S)  
Jeffrey Schlom et alFILING DATE  
September 30, 1996GROUP ART UNIT  
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

		Bos, J.L., <i>ras</i> Oncogenes in Human Cancer: A Review, <u>Cancer Research</u> 49, 4682-4689 (1989).
		Fossum, B. et al, CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21- <i>Ras</i> -derived peptide (GLY <sup>13</sup> >ASP), are cytotoxic towards a carcinoma-cell line harbouring the same mutation, <u>Cancer Immunol. Immunotherapy</u> 40, 165-162 (1995).

EXAMINER

DATE CONSIDERED

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

All references considered except where lined through. //KAC

//Karen A. Canella/ 7/15/2009/



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2026-4230US1SERIAL NO.  
09/155,590

Sheet 11 of 17

**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*APPLICANT(S)  
Jeffrey Schlom et alFILING DATE  
September 30, 1996GROUP ART UNIT  
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

EXAMINER INITIAL		Qin, H. et al, CD4+ T-cell immunity to mutated <i>ras</i> protein in pancreatic and colon cancer patients, <u>Cancer Research</u> 55, 2984-2987 (1995).
EXAMINER INITIAL		Abrams, S.I. et al, Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K- <i>ras</i> p21, <u>Eur. J. Immunol.</u> 25, 2588-2597 (1995).

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/





FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
2026-42300S1

SERIAL NO.  
09/155,590

**INFORMATION DISCLOSURE CITATION**

*(Use several sheets if necessary)*

APPLICANT(S)  
Jeffrey Schlom et al

FILING DATE  
September 30, 1996

GROUP ART UNIT  
1643

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

HA		Van Elsas, A. et al, Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 <i>Ras</i> peptid presented by HLA-A *0201, <i>Int. J. Cancer</i> 61, 389-396 (1995).
HA		Kiaris, H. et al, Mutations of <i>ras</i> genes in human tumours (review), <i>Int. J. Oncol.</i> 7, 413-421 (1995).

EXAMINER

*Hope Robinson Eudo*

DATE CONSIDERED

*3/21/00 10/5/00*

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
2026-4230US1

SERIAL NO.  
09/155.590

### INFORMATION DISCLOSURE CITATION

*(Use several sheets if necessary)*

**APPLICANT(S)**  
Jeffrey Schlom et al

**FILING DATE**  
**September 30, 1996**

GROUP ART UNIT  
1643

**U.S. PATENT DOCUMENTS**

[illegible]**FOREIGN PATENT DOCUMENTS**[illegible]

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

FAR		Fossum, B. et al, Overlapping epitopes encompassing a point mutation (12 Gly > Arg) in p21
		<i>ras</i> can be recognized by HLA-DR, -DP and -DQ restricted T cells, <u>Eur. J. Immunol.</u> 23, 2687-2691 (1993).
HAR		Gedde-Dahl III et al, T-cell responses against products of oncogenes: generation and
		characterization of human T-cell clones specific for p21 <i>Ras</i> -derived synthetic peptides, <u>Human Immunol.</u> 33, 266-274 (1992).

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DCKET NO.  
2026-4230US1SERIAL NO.  
09/155,590

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)  
Jeffrey Schiom et alFILING DATE  
September 30, 1996GROUP ART UNIT  
1643

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

HAR		Salter, R.D. et al, Impaired assembly and transport of HLA-A and B antigens in a mutant TxB hybrid, <u>EMBO J.</u> , 5, 943-949 (1986).
		Jung, S. et al, Human T lymphocytes recognize a peptide of single point-mutated, oncogenic <i>ras</i> proteins, <u>J. Exp. Med.</u> , 163, 273-276 (1991).
EXAMINER		
	DATE CONSIDERED 3/21/00 wls/ta	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC  
/Karen A. Canella/ 7/15/2009/

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2026-4230051SERIAL NO.  
09/165,590

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)  
Jeffrey Schiom et alFILING DATE  
September 30, 1996GROUP ART UNIT  
1643

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

HAR		Khleif, S.N. et al, Induction of T cell responses after vaccination with specific <i>Ras</i> mutant peptides in cancer patients, <u>Proceedings of the American Association for Cancer Research</u> , Vol. 37, March 1996, Abstract.
HAR		Tsang, K.Y. et al, Induction of Human Cytotoxic T Cell Lines Directed Against Point-Mutated p21 <i>Ras</i> -Derived Synthetic Peptides, <u>Vaccine Research</u> , Vol. 3, No. 4, p. 183-193, 1994.

EXAMINER

Hope Robinson Field

DATE CONSIDERED

3/21/00 105/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2026-42300S1SERIAL NO.  
09/155,590

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)  
Jeffrey Schlom et alFILING DATE  
September 30, 1996GROUP ART UNIT  
1643

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

EXAMINER	GA	Gaudernack, G., T cell responses against mutant <i>ras</i> , a basis for novel cancer vaccines
		<i>Immunotechnology</i> 2 (1996), pp. 3-9.
EXAMINER	AR	Carbone et al, Feasibility of immunization with individualized mutant <i>ras</i> and p53 peptides
		in patients with solid tumors, <i>Proc. ASCO</i> Vol. 14, p. 546 (6/14/95).
EXAMINER		
	DATE CONSIDERED	3/21/00 10/5/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/